COMPANY PROFILE

Zhimeng Biopharma

Discovering and developing the most effective, safe and affordable drugs to improve the quality of life of patients in China and abroad

Huangpu, ChinaFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Zhimeng Biopharma

Zhimeng Biopharma, founded in 2017 and based in Shanghai's Zhangjiang High Tech Park, is a biotech startup focused on developing medicines for chronic hepatitis B (CHB) and related liver diseases. The company aims to discover and develop the most effective, safe, and affordable drugs to improve the quality of life for patients both in China and globally. Zhimeng employs a comprehensive strategy to combat CHB by targeting the hepatitis B virus (HBV) with multiple approaches and restoring the host immune systems. The company serves patients suffering from chronic hepatitis B and other liver diseases, operating primarily in the pharmaceutical and biotech markets. Zhimeng's business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and sale of these drugs, as well as potential partnerships and licensing agreements. The company is also involved in early clinical development programs for drug candidates targeting neurological conditions such as epilepsy, pain, depression, and stroke.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Huangpu, China
Employees: 7
Open positions: None listed
Dealroom signal: 40.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Nov 2021	$48M	$193M	Dyee Capital · Dawu Venture Capital · Advantech Capital · Fortune Venture	↗
SERIES AOther financing	Nov 2020	$35M	$710M	Photon Fund · State Development & Investment Corporation (SDIC) · Oceanpine Capital	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Zhimeng Biopharma website traffic

Latest recorded traffic for Zhimeng Biopharma is 380 monthly website visits, down 35.6% over the last three months. Zhimeng Biopharma's team declined 12.5% over the past year.

Latest monthly visits380 3-month web change-35.6% 1-year team growth-12.5%

Monthly website visitsFeb 2020–Feb 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
CGCSPC Pharmaceutical GroupCSPC Pharmaceutical Group is a pharmaceutical group in China	Shijiazhuang, China	Operational
WAWaveBreakSmall-molecule therapeutics for neurodegenerative diseases	Cambridge, United Kingdom	Operational
FBFreeOx BiotechAdvancing Stroke Care through Innovation and Precision Medicine	Barcelona, Spain	Operational
CPCOMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions	London, United Kingdom	Operational
RTRewind TherapeuticsFirst-in-class remyelinating therapies for myelin-related diseases	Belgium, United States	Operational
APAudioCure PharmaPharmaceutical company with a focus on hearing impairments	Berlin, Germany	Operational